Introduction
============

Colon cancer (CRC) is the fourth leading cause of cancer-related deaths throughout the world after lung, breast, and prostate cancer. Based on the GLOBOCAN data, more than 1.8 million newly diagnosed carcinoma cases and 881,000 deaths related to this disease occurred in 2018 worldwide ([@b1-or-0-0-7216]). Colon adenocarcinoma (COAD) is one of the most common pathological types of colon cancer ([@b2-or-0-0-7216]). In recent years, colon adenocarcinoma has a significant upward trend in morbidity and mortality ([@b3-or-0-0-7216]), especially in Western developed countries and Asian developing countries ([@b4-or-0-0-7216]). Although, there are many treatments, including surgery and chemotherapy, the five-year survival rate of COAD is still not promising ([@b5-or-0-0-7216]). Late diagnosis, unreliable biomarkers and therapeutic targets have become major obstacles in the treatment of colon adenocarcinoma ([@b6-or-0-0-7216]). Therefore, early diagnosis and treatment are essential for the improvement of the prognosis and quality of life of the patients. Finding new targets in COAD may provide new alternatives and insights for comprehensive management strategies for COAD patients.

Integrins belong to heterodimeric surface receptors, which are composed of non-covalently associated α and β subunits, and as far as we know, the integrin family consists of 18α and 8β members ([@b7-or-0-0-7216]--[@b11-or-0-0-7216]). *ITGA*, a subfamily of integrins, has an α subunit composed of a seven-bladed β-propeller, a thigh, and two calf domains ([@b12-or-0-0-7216]). There is an I domain (also called A domain), composed of \~200 amino acids inserted between blades 2 and 3 in the β-propeller, and contained in nine of the 18 integrin α chains ([@b13-or-0-0-7216]). There are also domains that bind Ca^2+^ on the lower side of the blades facing away from the ligand-binding surface which are contained in the last three or four blades of the β propeller. Ligand binding is influenced by Ca^2+^ binding to these sites allosterically ([@b14-or-0-0-7216],[@b15-or-0-0-7216]). Previous research has revealed that the integrin family mediates signal transduction by binding to the extracellular matrix via adhesion receptors on its surface ([@b16-or-0-0-7216]). Each integrin has multiple activation states ([@b12-or-0-0-7216]), and exerts effects through cascaded amplification of various paths ([@b17-or-0-0-7216]). Extensive studies have revealed that integrins could function as signaling molecules through the cell membrane in either direction: 'inside-out signaling' caused by extracellular stimulation that causes intracellular linin and kindlin to bind to the cytoskeleton, leaving the extracellular domain in a high affinity state ([@b8-or-0-0-7216],[@b18-or-0-0-7216]--[@b20-or-0-0-7216]); and 'outside-in signaling', a complicated process in which the heterodimeric adhesion receptors of the integrins mediate cell adhesion to the extracellular matrix (ECM), then activate integrins to engage and interact with the cytoskeleton in order to activate a variety of intracellular signaling pathways ([@b12-or-0-0-7216]), which enhance binding of activated integrin ligands and allow for the perception of the intracellular environment ([@b9-or-0-0-7216],[@b20-or-0-0-7216],[@b21-or-0-0-7216]). These integrins could control cell attachment, movement, growth and differentiation, as well as survival ([@b12-or-0-0-7216],[@b22-or-0-0-7216]).

Integrins modulate muititudinal human pathologies including thrombotic diseases, infectious diseases, inflammation, fibrosis, and cancer ([@b17-or-0-0-7216]). In cancer, members of the integrin family of pattern recognition receptors participate in many cellular processes in the body, including adhesion, metastatic spread of tumor cells, and identification ([@b22-or-0-0-7216]). In addition to altering the interaction of cells with the surrounding environment, the proliferation, survival and differentiation of cancer cells can be promoted by integrins through growth factors such as EGFR, VEGFR interaction, or tyrosine kinase receptors ([@b23-or-0-0-7216]). Integrins, as cell adhesion receptors, are also observed and have been reported in various types of cancer, such as multiple myeloma ([@b24-or-0-0-7216]), NSCLC ([@b25-or-0-0-7216]), glioma ([@b26-or-0-0-7216]), ovarian cancer ([@b27-or-0-0-7216]) and oral squamous cell carcinoma ([@b28-or-0-0-7216]). However, the potential mechanism and application value of *ITGA* genes remain elusive. Therefore, the aim of the present study was to explore the potential application of *ITGA* genes of COAD in the perspective of diagnosis and prognosis by using an RNA-sequencing (RNA-Seq) dataset from The Cancer Genome Atlas (TCGA; <http://tcga-data.nci.nih.gov/>).

Materials and methods
=====================

### Patient information

TCGA databases were accessed on October 30, 2018, and a total of 456 COAD patient clinical parameters which consisted of 480 tumor and 41 adjacent normal tissue samples were collected. Clinical parameter information including sex, age, survival time (days), survival status and tumor-node-metastasis (TNM) stage were obtained.

### Bioinformatics analysis of ITGA genes

To study the biological enrichment function of the *ITGA* subfamily, the online tool Database for Annotation, Visualization, and Integrated Discovery (DAVID) (<https://david.ncifcrf.gov/>; version 6.8; accessed January 5, 2019) ([@b29-or-0-0-7216],[@b30-or-0-0-7216]), containing gene ontology (GO) enrichment functional analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis ([@b31-or-0-0-7216],[@b32-or-0-0-7216]) was used. An enrichment P-value \<0.05 was considered as significant from a statistical perspective. Gene ontology includes 3 independent modules, biological processes (BP), molecular functions (MF), and cellular components (CC) ([@b31-or-0-0-7216]). GO terms of *ITGA* genes were also obtained using the Biological Networks Gene Ontology tool (BiNGO) in Cytoscape_version 3.6.1 ([@b33-or-0-0-7216]). Gene-gene interactions of *ITGA* genes were then investigated using Gene Multiple Association Network Integration Algorithm (GeneMANIA, <http://www.genemania.org/>, accessed December 25, 2018) ([@b34-or-0-0-7216]). Protein-protein interactions (PPI) of *ITGA* genes were performed using the Search Tool for the Retrieval of Interacting Genes (STRING; <https://string-db.org/>, accessed November 19, 2018) ([@b35-or-0-0-7216],[@b36-or-0-0-7216]).

### mRNA expression levels of ITGA genes and diagnostic receiver operating characteristic (ROC) curves

The mRNA expression levels of *ITGA* genes were presented by box plots and scatter plots. A box plot of *ITGA* genes was downloaded from the Metabolic gEne RApid Visualizer (MEARV) (<http://merav.wi.mit.edu/>, accessed January 21, 2019) ([@b37-or-0-0-7216]), while a scatter plot was generated from the TCGA dataset to integrate cancer and adjacent normal tissues of mRNA expression levels at 75% cut-off values. Diagnostic ROC curves investigated the statistically significant expression of tumor tissues and adjacent normal tissues in TCGA cohort.
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----------------------------------------------------------------------------------

### COAD patient tissue samples

COAD patient tissues, 30 in all, including tumor tissues and paired adjacent normal tissues, were collected (from April to June 2018) at the Department of Colorectal and Anal Surgery of The First Affiliated Hospital of Guangxi Medical University (Nanning, China). All patients signed an informed consent form, and the experimental protocol was approved by the Ethics Committee of the First Affiliated Hospital of Guangxi Medical University. \[No. 2019(KY-E-001)\]. Immediately after surgery, the tissue was placed in RNA protection solution and transferred to a −80°C refrigerator for preservation. The postoperative pathological diagnosis was COAD.

### Detection of ITGA8 expression by reverse transcription- quantitative polymerase chain reaction (RT-qPCR)

RT-qPCR was performed to assess *ITGA8* expression in COAD tissue samples, including tumor and adjacent normal tissues. TRIzol^®^ reagent (15596026; Invitrogen; Thermo Fisher Scientific, Inc.) was used to extract total RNA from tissues. Total RNA concentration was detected by NanoDrop One (Thermo Fisher Scientific, Inc.). And the RNA was reverse-transcribed (20-µl reaction system) applying a reverse transcription kit (Applied Biosystems; Thermo Fisher Scientific, Inc.) to create cDNA. Then in accordance with the FastStart Universal SYBR Green Master (ROX) kit (Roche Diagnostics) and the Applied Biosystems Quantsudio™ Real-Time PCR System (Q6) operation guide (Applied Biosystems; Thermo Fisher Scientific, Inc.), the reaction procedure was set up. The reaction conditions used were as follows: Pre-denaturation at 95°C for 10 min; then denaturation at 95°C for 15 sec, 60°C extension for 60 sec, 40 cycles; finally denaturation at 95°C for 15 sec, 60°C for 1 min, 95°C for 30 sec, and 60°C for 15 sec. GAPDH was used as an internal reference gene, and the primer sequences of *ITGA8* and GAPDH were synthesized by Sangon Biotech Co., Ltd. The primer sequences were as follows: GAPDH forward, 5′-TGGTCCCTGCTCCTCTAAC-3′ and reverse, 5′-GGCTCAATGGCGTACTCTC-3′; and *ITGA8* forward, 5′-GCTGCTGGGGAGTTTACTGG-3′ and reverse, 5′-GATGCCATCTGTTCTCCCGTG-3′. The gene expression level in the present study was calculated using the 2^−∆∆Cq^ method ([@b38-or-0-0-7216]).

### Survival analysis

In TCGA database, 438 COAD patients were categorized into two groups namely a high and low-expression group, which were based on the 75% cut-off value of gene expression. Kaplan-Meier survival analysis was performed for sex, age, and stage, respectively. Then overall survival (OS) was determined to evaluate the prognostic value of COAD patients. Furthermore, sex, age, and TNM stage were adjusted using Cox proportional hazards regression model in TCGA database.

### Gene set enrichment analysis (GSEA)

To further explore the potential value of biological processes and pathways, multivariate prognostic significance of the *ITGA5* gene was grouped into low and high expression categories based on the 75% cut-off value of the expression levels. GSEA (<http://software.broadinstitute.org/gsea/index.jsp>, downloaded January 20, 2018) ([@b39-or-0-0-7216],[@b40-or-0-0-7216]) was conducted to investigate underlying mechanisms by using the Molecular Signatures Database (MSigDB) c2 (c2.cp.kegg.v6.2.symbols.gmt) and c5 (c5.all.v6.2.symbols.gmt) ([@b41-or-0-0-7216]). The enrichment gene sets in GSEA were identified as statistically significant when a nominal P-value \<0.05 and a false discovery rate (FDR) \<0.25 were attained.

### Statistical analysis

Kaplan-Meier survival analysis and the log-rank test were conducted to assess different subgroups categorized by clinical and gene variables. Adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) were obtained using univariate and multivariate Cox proportional hazards models. TNM stage was selected to set up a Cox proportional hazard regression model. The paired t-test was applied for comparison of data between COAD tumors and adjacent normal tissues. A P\<0.05 indicated that the differences exhibited statistical significance. The FDR in GSEA was adjusted for multiple testing according to the Benjamini-Hochberg procedure ([@b42-or-0-0-7216],[@b43-or-0-0-7216]). All of the aforementioned statistical analyses were performed with SPSS Statistics software version 20.0 (IBM Corp.). Vertical scatter plots, ROC and survival curves were plotted using GraphPad Prism v.7.0 (GraphPad Software, Inc.).

Results
=======

### Baseline patient characteristics in TCGA

The expression of the *ITGA* subfamily of related genes was included from the TCGA RNAseq database. Firstly, information concerning tumor and adjacent normal tissues was isolated. Then clinical information was integrated with gene expression. In addition, cases that had no clinical prognostic information and people who had a survival time of 0 were excluded. Finally, information on the 438 COAD patient tumor samples and 41 adjacent normal tissue samples was obtained. Detailed baseline characteristics of the 438 COAD patients from the TCGA database are summarized in [Table I](#tI-or-0-0-7216){ref-type="table"}. It was revealed that sex and age were not correlated with OS (all P\>0.05). However, TNM stage was notably associated with OS (log-rank test P\<0.001, adjusted P\<0.001).

### Analysis of ITGA subfamily mRNA expression levels in TCGA databases

The 75% cut-off value of gene expression levels was used to categorize COAD patients into low-level groups and high-level groups. Then TNM stage was used for adjustment of these genes. Multivariate analysis indicated that *ITGA5* exhibited statistical significance \[P=0.016; HR (95% CI)=1.681 (1.100--2.570)\] ([Table II](#tII-or-0-0-7216){ref-type="table"}).

### Bioinformatics analysis of the ITGA genes

GO term enrichment analysis of *ITGA* genes revealed that biological processes mainly involved cell adhesion and the integrin-mediated signaling pathway ([Fig. 1A](#f1-or-0-0-7216){ref-type="fig"} and [S1](#SD1-or-0-0-7216){ref-type="supplementary-material"}). KEGG pathway analysis mainly involved focal adhesion, the PI3K/AKt signaling pathway and regulation of actin cytoskeleton ([Fig. 1B](#f1-or-0-0-7216){ref-type="fig"} and [S2](#SD1-or-0-0-7216){ref-type="supplementary-material"}). The interaction networks of gene-gene and protein-protein indicated that *ITGA* genes had co-expression with each other and with complex gene-gene and protein-protein interaction networks ([Fig. 2A and B](#f2-or-0-0-7216){ref-type="fig"}).

### Analysis of ITGA subfamily gene expression levels in tumor and adjacent normal tissues based on TCGA

Box plots of the expression levels of 16 genes are presented in [Fig. 3](#f3-or-0-0-7216){ref-type="fig"} (*ITGA1* and *ITGA4* are not presented). *ITGA2B, ITGA6, ITGA8* and *ITGAL* were high in expression in adjacent normal tissues compared to tumor tissues, while the other 12 genes were high in tumor tissues compared to normal tissues.

The scatter diagrams were used to present the expression between the tumor and adjacent tissues ([Fig. 4](#f4-or-0-0-7216){ref-type="fig"}) and the results revealed that *ITGA2B, ITGA5, ITGA10, ITGAD, ITGAE* and *ITGAV* exhibited no statistical significant differences, however the other genes significantly differed). It was also observed that the majority of genes were expressed at a significantly low level in tumor tissues, while the expression of adjacent normal tissues was high.

The possible potential application of *ITGA* genes in COAD tumor and adjacent tissues was further explored. The diagnostic ROC analysis of *ITGA* genes in the TCGA COAD cohort showed that *ITGA2, ITGA3, ITGA4, ITGA6, ITGA7, ITGA8, ITGA11, ITGAL, ITGAM and ITGAX* can serve as potential diagnostic biomarker for COAD (all P\<0.05). Notably, *ITGA8* \[AUC (95% CI)=0.989 (0.980--0.997)\] exhibited a high diagnostic value distinguishing tumor tissues and adjacent normal tissues of COAD (P\<0.0001). All ROC curves are presented in [Fig. 5](#f5-or-0-0-7216){ref-type="fig"}.

### Validation of ITGA8 expression in clinical samples

To investigate and further validate the possible function of *ITGA8* expression in the clinical sample cohort, the paired t-test was performed between COAD tumors and adjacent normal tissues (P=0.041), and a scatter diagram was selected to compare the expression levels of the clinical sample cohort and TCGA cohort ([Fig. 6A and B](#f6-or-0-0-7216){ref-type="fig"}). The results indicated that both cohorts exhibited a significantly high expression level in adjacent normal tissues. Then, the diagnostic ROC curve was used to study the underlying role of *ITGA8* in clinical samples. The result revealed that *ITGA8* had a significant value \[P=0.005, AUC (95% CI)=0.704 (0.577--0.831)\]; ([Fig. 6C](#f6-or-0-0-7216){ref-type="fig"}).

### Prognostic survival analysis

To further explore the survival values, survival analysis curves were drawn according to gene expression ([Fig. 7](#f7-or-0-0-7216){ref-type="fig"}). Only *ITGA5* and *ITGA10* exhibited statistical significance (P\<0.05). Consequently, it was observed that a high level of *ITGA5* and *ITGA10* expression were linked with poor prognosis for OS (log-rank test, P=0.0045 and P=0.0244).

### GSEA

In the present study, prognostic value of *ITGA5* was assessed to investigate its potential in GO terms and KEGG pathways in COAD prognosis. GSEA revealed that the c5 gene sets indicated that the high expression of *ITGA5* may be mostly enriched in ECM ([Fig. 8A-I](#f8-or-0-0-7216){ref-type="fig"}). In addition, the c2 gene sets were significantly involved in focal adhesion, the chemokine signaling pathway, pathways in cancer and ECM receptor interaction ([Fig. 9A-I](#f9-or-0-0-7216){ref-type="fig"}).

Discussion
==========

As is recognized, the occurrence and development of tumors are caused by multiple factors, and the homeostasis of the internal environment is crucial. Integrins are a family of cell adhesion proteins that can mediate cell-cell, cell-extracellular matrix (ECM), cell-pathogen interactions and signaling through adhesion receptors ([@b7-or-0-0-7216],[@b12-or-0-0-7216],[@b44-or-0-0-7216],[@b45-or-0-0-7216]). The integrins are the main receptors for extracellular matrix proteins like collagen, fibronectin and laminin. In addition, integrins play a fundamental role in various biological processes via cellular adhesion mechanisms ([@b10-or-0-0-7216],[@b46-or-0-0-7216]). The *ITGA* family is a subfamily of integrins, and certain previous studies had reported the relationship between the *ITGA* subfamily genes and colorectal cancer. Yang *et al* reported that *ITGA2* was significantly overexpressed in both primary colon tumors and liver metastases with tissues from 43 patients as was determined by western blotting, immunohistochemistry and tissue microarray ([@b47-or-0-0-7216]). The expression of *ITGA3* was linked to other genes by cDNA Array and immunohistochemistry in colorectal cancer. It was revealed that *ITGA3* was overexpressed in tumor tissues. In a study by Waisberg *et al*, the expression of *ITGAV* was assessed by PCR and immunohistochemistry in adult CRC patients (n=114), and the results indicated that the overexpression of *ITGAV* was associated with higher progression and spread of CRC ([@b48-or-0-0-7216]). *ITGA* subfamily genes have also been reported in other types of cancer. *ITGA1* was recently revealed to be associated with an invasive metastatic phenotype in hepatocellular and prostate cancers ([@b49-or-0-0-7216],[@b50-or-0-0-7216]). Other studies revealed that *ITGA2* was expressed in gastric cancer ([@b51-or-0-0-7216]), pancreatic cancer ([@b52-or-0-0-7216]) and pancreatic ductal adenocarcinoma (PDAC) ([@b53-or-0-0-7216]). In addition, *ITGA10* was expressed in B-cell lymphoma ([@b54-or-0-0-7216]) and *ITGA11* was expressed in breast cancer ([@b55-or-0-0-7216]), lung squamous cancer ([@b56-or-0-0-7216]) and neck squamous cell carcinoma ([@b57-or-0-0-7216]).

However, there is little knowledge about the relationship between the *ITGA* subfamily genes and COAD. To the best of our knowledge, this was the first time that TCGA RNA sequencing dataset and PCR detection were used to investigate diagnostic and prognostic values of *ITGA* subfamily genes in COAD. The present results indicated that the mRNA expression levels of the *ITGA* subfamily genes were correlative with COAD in diagnosis and prognosis. Gene function enrichment analysis revealed that *ITGA* genes were significantly involved in biological processes, pathways of cell adhesion and the integrin-mediated signaling pathway. In addition, co-expression analysis revealed that *ITGA* genes were co-expressed with each other at both the gene and protein levels.

It was determined that *ITGA2, ITGA6, ITGA11* and *ITGAX* were significantly expressed at a high level in cancer tissues, while *ITGA1, ITGA3, ITGA4, ITGA7, ITGA8, ITGA9, ITGAL* and *ITGAM* were significantly expressed at a high level in adjacent normal tissues in a TCGA cohort. The results of ROC curves revealed that *ITGA8* had a high diagnostic value \[AUC (95% CI)=0.989 (0.980--0.997)\]. Kok-Sin *et al* reported that *ITAGA8* was considered as a potential diagnostic marker, serving as a tumor suppressor gene as determined via DNA methylation and gene expression profiling assays, in colorectal cancer ([@b58-or-0-0-7216]). In a study by Yang *et al*, the *ITGA8* mRNA and protein levels were assessed in 483 LUAD tissues and 59 adjacent tissues, and the results indicated that the expression of *ITGA8* was downregulated in LUAD ([@b59-or-0-0-7216]). Then, to further validate the expression of the *ITGA8* gene in cancer and adjacent tissues of COAD, RT-qPCR was performed, and the results revealed that *ITGA8* was significantly expressed at a high level in adjacent normal tissues of COAD. Thus, it was hypothesized that *ITGA8* may be a potential diagnostic marker in COAD.

Survival prognosis analysis results revealed that the high expression levels of *ITGA5* and *ITGA1*0 were associated with poor prognosis, while Kaplan-Meier curves from multivariate survival analysis revealed that the low expression of *ITGA5* was linked to favorable prognosis of COAD OS in the TCGA cohort. Especially *ITGA5* was an independent prognosis factor for OS of COAD patients. However, previous studies revealed that overexpression of *ITGA5* indicated poor prognosis. A study by Shang *et al* revealed that low expression of *ITGA5* indicated a good overall survival (OS) or relapse-free survival (RFS) of HBV-related HCC patients ([@b60-or-0-0-7216]). Research by Haider *et al* revealed that high expression of *ITGA5* was associated with a short survival time of pancreatic ductal adenocarcinoma (PDAC) patients ([@b61-or-0-0-7216]). In addition, the results from a study by Yan *et al* indicated that the upregulated expression of *ITGA5* reduced the overall survival of gastric cancer (GC) patients ([@b62-or-0-0-7216]). Similar results were also reported in non-small cell lung cancer (NSCLC) ([@b63-or-0-0-7216]) and glioblastoma cell invasion ([@b64-or-0-0-7216]).

The results of GSEA in the present study indicated that *ITGA5* (also known as *FNRA, CD49e, VLA-5* and *VLA5A*) was markedly associated with the survival and progression of COAD, and the underlying mechanism of focal adhesion, ECM receptor interaction and extracellular matrix (ECM) were associated with its biological functions. Integrin α subunit and β subunit form heterodimeric integral membrane proteins that function in cell surface adhesion and signaling ([@b16-or-0-0-7216]). Previous studies have reported that *ITGA5* mediated cell adhesion and migration in human hepatocarcinoma cells by activating focal adhesion kinase (FAK) ([@b65-or-0-0-7216]). A study by Yang and Wang revealed that *ITGA5* participated in pathways involving focal adhesion and ECM-receptor interaction in osteosarcoma ([@b66-or-0-0-7216]). In addition, *ITGA5* may be involved in bladder cancer progression by extracellular matrix-receptor interaction and focal adhesion ([@b67-or-0-0-7216]). In the present study, the results of GSEA indicated that *ITGA5* may serve as an important adhesion molecule through its adhesion mechanism in COAD. To be specific, *ITGA5* may act on COAD via the FAK signaling pathway and ECM receptor signaling pathway. However, these results require further research to be confirmed.

Although the present study was the first to reveal the role of the *ITGA* subfamily in the diagnosis and prognosis of COAD, it still has certain limitations. First, all the information was obtained from open databases, and the medical parameters were incomplete. Other potential influencing factors like tumor location, tumor size, lymphatic metastasis, and venous metastasis were not included. Second, disease-free survival should be listed as a factor to assess COAD prognosis. Third, the study required a larger multi-center and multi-regional as well as a multi-ethnic sample population. Fourth, the present study required further investigation at the protein level and COAD prognosis prediction, as well as further *in vivo* and *in vitro* experimental validation.

In conclusion, the present study revealed that the *ITGA* subfamily mRNA expression was associated with the diagnosis and prognosis of COAD. Combined with ROC curves and RT-qPCR verification, the *ITGA8* expression level may be a potential diagnostic marker of COAD. In addition, survival analysis indicated that the expression of *ITGA5* may serve as a prognostic biomarker of COAD. However, the present results still require further exploration and verification in the future.
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###### 

Baseline patient characteristics in a TCGA cohort.

                                                                 OS                                  
  -------------------------------------------------------- ----- ---- ------- ---------------------- ---------
  Age (years)                                                                                        
    \<65                                                   168   30   NA      1                      0.17
    ≥65                                                    268   67   82.5    1.353 (0.879--2.081)   
    Missing^[a](#tfn1-or-0-0-7216){ref-type="table-fn"}^   2                                         
  Sex                                                                                                
    Male                                                   234   54   82.5    1                      0.545
    Female                                                 204   44   NA      0.884 (0.593--1.318)   
  Stage                                                                                              
    1 and 2                                                240   34   101.4   1                      \<0.001
    3 and 4                                                187   59   62.7    2.684 (1.758--4.099)   
    Missing^[b](#tfn2-or-0-0-7216){ref-type="table-fn"}^   11                                        

Missing, information of age was unknown in 2 patients

Missing, information of TNM stage was not reported in 10 patients. TCGA, The Cancer Genome Atlas; OS, overall survival; MST, median survival time; 95% CI, 95% confidence interval; HR, hazards ratio; NA, not available.

###### 

Prognostic values of *ITGA* subfamily gene expression in COAD of a TCGA cohort.

                   OS                                  
  ---------- ----- ---- ------- ---------------------- -------
  *ITGA1*                                              
    Low      329   77   3,042   1                      0.303
    High     109   21   2,134   0.775 (0.477--1.259)   
  *ITGA2*                                              
    Low      329   78   2,532   1                      0.176
    High     109   20   NA      0.711 (0.434--1.165)   
  *ITGA2B*                                             
    Low      329   74   2,475   1                      0.792
    High     109   24   NA      1.064 (0.670--1.691)   
  *ITGA3*                                              
    Low      329   70   2,532   1                      0.898
    High     109   28   2,047   0.971 (0.620--1.521)   
  *ITGA4*                                              
    Low      329   73   2,821   1                      0.434
    High     109   25   1,661   1.203 (0.757--1.912)   
  *ITGA5*                                              
    Low      329   73   2,821   1                      0.016
    High     109   25   2,047   1.681 (1.100--2.570)   
  *ITGA6*                                              
    Low      329   77   2,532   1                      0.284
    High     109   21   NA      0.767 (0.471--1.246)   
  *ITGA7*                                              
    Low      329   73   2,532   1                      0.763
    High     109   25   3,042   0.932 (0.59--1.472)    
  *ITGA8*                                              
    Low      329   80   2,475   1                      0.206
    High     109   18   NA      0.718 (0.430--1.199)   
  *ITGA9*                                              
    Low      329   62   2,821   1                      0.165
    High     109   36   2,047   1.340 (0.887--2.024)   
  *ITGA10*                                             
    Low      329   69   2,821   1                      0.069
    High     109   29   2,047   1.506 (0.969--2.343)   
  *ITGA11*                                             
    Low      329   70   2,821   1                      0.641
    High     109   28   1,910   1.111 (0.713--1.731)   
  *ITGAD*                                              
    Low      329   73   2,475   1                      0.801
    High     109   25   3,042   1.060 (0.672--1.672)   
  *ITGAE*                                              
    Low      329   80   2,475   1                      0.438
    High     109   18   NA      0.815(0.486--1.366)    
  *ITGAL*                                              
    Low      329   72   2,532   1                      0.173
    High     109   26   2,134   1.370 (0.871--2.156)   
  *ITGAM*                                              
    Low      329   72   2,821   1                      0.382
    High     109   26   2,134   1.222 (0.779--1.917)   
  *ITGAV*                                              
    Low      329   81   2,532   1                      0.327
    High     109   17   2,047   0.768(0.452--1.303)    
  *ITGAX*                                              
    Low      329   76   2,532   1                      0.665
    High     109   22   3,042   1.111(0.689--1.793)    

Adjusted P-value, adjustment for TNM stage. COAD, colon adenocarcinoma; *ITGA*, integrin α; OS, overall survival; MST, median survival time; 95% CI, 95% confidence interval; HR, hazards ratio; NA, not available.

[^1]: Contributed equally
